References for Chapter 4
Health Economic Considerations in Cardiovascular Drug Utilization

Renée J. G. Arnold, RPh, PharmD
William H. Frishman, MD


42. Eckman MH, Levine HJ, and Pauker SG: Making


108. Data on file, GlaxoSmithKline PLC.


124. Grover SA, Coupal L, Zowall H, et al.: Cost-effec-


